This record was last updated October 1, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin in combination with Pertuzumab with or without Toripalimab neoadjuvant therapy in patients with HER2-positive breast cancer.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-11; most recent amendment 2025-09-26.
Status change: Not Yet Recruiting → Recruiting2024-02-18